Predictive biomarkers for MGMT-promoter-methylated glioblastoma (A05)

点击翻译按钮获取中文摘要

By analysis of the mutational spectrum, DNA methylation patterns, chromosomal aberrations, and proteome profiles of tumor tissues from glioblastoma patients with O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation and response (>15 months progression-free-survival) vs. patients with no response (<6 months) to combined radiochemotherapy with temozolomide, we aim to identify novel predictive tissue-biomarkers for temozolomide response and resistance in glioblastoma patients. These novel predictive markers are expected to have a direct impact on clinical decision making with improved predictive power when compared to MGMT methylation status alone.